Strong Use of Composition-of-Matter Coverage: Patent protects the molecular structure of RHB-107, providing market exclusivity beyond method-of-use claims COVID-19 Therapeutic Use: Includes coverage ...

Revenue-generating with an exciting, diversified, largely externally funded, advanced development pipeline and multiple upcoming catalysts. Recent highlights: Mr. Ben-Asher continued: "Having ...

The Notification Letter has no immediate effect on the Company's listing on the Nasdaq Capital Market at this time, nor are the Company's business operations affected by receipt of the Notification ...

New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of opaganib[1] ...

Although study results show RedHill Biopharma’s irritable bowel syndrome with diarrhea drug Bekinda, improves stool consistency compared to a placebo, investors sent the drugmaker’s stock tumbling ...

The planned innovative Phase 2 study of RHB-2041 will be the first ever clinical study in Crohn's Disease (CD) patients who are all MAP-positive, and will correlate mucosal healing with MAP2 infection ...

TEL-AVIV, Israel and RALEIGH, N.C., Dec. 1, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that on ...

RedHill Biopharma Ltd. (NASDAQ:RDHL) announced Tuesday that it received a notice from the Nasdaq Stock Market regarding non-compliance with the minimum bid price requirement for continued listing on ...

Tel-Aviv, Israel-based RedHill Biopharma treated the last patient enrolled in its Bekinda’s 24 mg phase III clinical trial. Here’s what you should know. 1. The company expects results in the second ...

RedHill Talicia ® business transformed: Formation of Talicia Holdings Inc. (THI) and the U.S. co-commercialization partnership with Cumberland Pharmaceuticals ("Cumberland") (Nasdaq: CPIX), including ...